Evidence map›Paper›PMID 33517499›Full record

ArticleArchives of toxicology2021

Development of versatile and potent monoquaternary reactivators of acetylcholinesterase.

Lukas Gorecki, Vendula Hepnarova, Jana Zdarova Karasova, Martina Hrabinova, Charlotte Courageux, José Dias, Tomas Kucera, Tereza Kobrlova, Lubica Muckova, Lukas Prchal and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 3 countries.

Lukas GoreckiBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Vendula HepnarovaBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Jana Zdarova KarasovaBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Martina HrabinovaBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Charlotte CourageuxDepartement de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale Des Armées, 1 Place Générale Valérie André, 91220, Brétigny-sur-Orge, France.
José DiasDepartement de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale Des Armées, 1 Place Générale Valérie André, 91220, Brétigny-sur-Orge, France.
Tomas KuceraDepartment of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic.
Tereza KobrlovaBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Lubica MuckovaBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Lukas PrchalBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
David MalinakBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Daniel JunBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Kamil MusilekBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
Franz WorekBundeswehr Institute of Pharmacology and Toxicology, Neuherbergstrasse 11, 80937, Munich, Germany.
Florian NachonDepartement de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale Des Armées, 1 Place Générale Valérie André, 91220, Brétigny-sur-Orge, France.
Ondrej SoukupBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic. ondrej.soukup@fnhk.cz.ORCID 0000-0001-6376-8701
Jan KorabecnyBiomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic. jan.korabecny@fnhk.cz.ORCID 0000-0001-6977-7596
University Hospital Hradec Králové · CZUniversität der Bundeswehr München · DEUniversity of Defence · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To date, the only treatments developed for poisoning by organophosphorus compounds, the most toxic chemical weapons of mass destruction, have exhibited limited efficacy and versatility. The available causal antidotes are based on reactivation of the enzyme acetylcholinesterase (AChE), which is rapidly and pseudo-irreversibly inhibited by these agents. In this study, we developed a novel series of monoquaternary reactivators combining permanently charged moieties tethered to position 6- of 3-hydroxypyridine-2-aldoxime reactivating subunit. Highlighted representatives (21, 24, and 27; also coded as K1371, K1374, and K1375, respectively) that contained 1-phenylisoquinolinium, 7-amino-1-phenylisoquinolinium and 4-carbamoylpyridinium moieties as peripheral anionic site ligands, respectively, showed efficacy superior or comparable to that of the clinically used standards. More importantly, these reactivators exhibited wide-spectrum efficacy and were minutely investigated via determination of their reactivation kinetics in parallel with molecular dynamics simulations to study their mechanisms of reactivation of the tabun-inhibited AChE conjugate. To further confirm the potential applicability of these candidates, a mouse in vivo assay was conducted. While K1375 had the lowest acute toxicity and the most suitable pharmacokinetic profile, the oxime K1374 with delayed elimination half-life was the most effective in ameliorating the signs of tabun toxicity. Moreover, both in vitro and in vivo, the versatility of the agents was substantially superior to that of clinically used standards. Their high efficacy and broad-spectrum capability make K1374 and K1375 promising candidates that should be further investigated for their potential as nerve agents and insecticide antidotes.

Indexed as

AcetylcholinesteraseAnimalsAntidotesCholinesterase ReactivatorsFemaleMaleMiceMice, Inbred BALB CMolecular Dynamics SimulationOximesStructure-Activity RelationshipAcetylcholinesteraseAntidotesCholinesterase ReactivatorsOximesAcetylcholinesteraseButyrylcholinesteraseInsecticidesNerve agentsOrganophosphatesOrganophosphorus compoundsOxime reactivator

Identifiers

PMID33517499
OpenAlexW3126358963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.